| Jul 31 |
Wall Street Analysts See a 37.6% Upside in Corcept (CORT): Can the Stock Really Move This High?
|
| Jul 31 |
Corcept Therapeutics Second Quarter 2024 Earnings: Beats Expectations
|
| Jul 30 |
Corcept Therapeutics: Q2 Gains Overshadowed By Generic Competition And Speculative Pipeline
|
| Jul 30 |
Corcept (CORT) Q2 Earnings & Revenues Surpass Estimates
|
| Jul 30 |
Unveiling 8 Analyst Insights On Corcept Therapeutics
|
| Jul 30 |
Corcept Therapeutics Incorporated (CORT) Q2 2024 Earnings Call Transcript
|
| Jul 29 |
Corcept Therapeutics (CORT) Q2 Earnings and Revenues Beat Estimates
|
| Jul 29 |
Corcept: Q2 Earnings Snapshot
|
| Jul 29 |
Corcept Therapeutics GAAP EPS of $0.32 beats by $0.10, revenue of $163.8M beats by $8.58M
|
| Jul 29 |
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
|
